# EDGAR Filing Document

**Accession Number:** 0001809122
**File Stem:** 0001999371-25-011273
**Filing Date:** 2025-8
**Character Count:** 14612
**Document Hash:** fe7a9e64f34d8e383d319b3783641186
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001999371-25-011273.hdr.sgml**: 20250813

**ACCESSION NUMBER**: 0001999371-25-011273

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250813

**DATE AS OF CHANGE**: 20250813

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CureVac N.V.
- **CENTRAL INDEX KEY:** 0001809122
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** P7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-91630
- **FILM NUMBER:** 251213344

**BUSINESS ADDRESS:**
- **STREET 1:** PAUL-EHRLICH-STRABE 15 TUBINGEN
- **CITY:** BADEN-WURTTEMBERG
- **STATE:** 2M
- **ZIP:** 72076
- **BUSINESS PHONE:** 49 7071 9883 0

**MAIL ADDRESS:**
- **STREET 1:** PAUL-EHRLICH-STRABE 15 TUBINGEN
- **CITY:** BADEN-WURTTEMBERG
- **STATE:** 2M
- **ZIP:** 72076

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CureVac B.V.
- **DATE OF NAME CHANGE:** 20200410
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GSK plc
- **CENTRAL INDEX KEY:** 0001131399
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**BUSINESS ADDRESS:**
- **STREET 1:** 79 NEW OXFORD STREET
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** WC1A 1DG
- **BUSINESS PHONE:** 011442080475000

**MAIL ADDRESS:**
- **STREET 1:** 79 NEW OXFORD STREET
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** WC1A 1DG

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GSK PLC
- **DATE OF NAME CHANGE:** 20220516

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GLAXOSMITHKLINE PLC
- **DATE OF NAME CHANGE:** 20010105

## Exhibit 99.1

**Exhibit**

**Schedule A – Item 2(c)**

**GSK**

**Directors and Executive Officers**

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**Name** | &nbsp;&nbsp;**Business Address** | &nbsp;&nbsp;**Principal Occupation or Employment** | &nbsp;&nbsp;**Citizenship** |
| ***Board of Directors*** | ***Board of Directors*** | ***Board of Directors*** | ***Board of Directors*** |
| Sir Jonathan Symonds CBE | 79 New Oxford Street, London, WC1A 1DG, United Kingdom | Chair and Company Director | British |
| Emma Walmsley | 79 New Oxford Street, London, WC1A 1DG, United Kingdom | Executive Director | British |
| Julie Brown | 79 New Oxford Street, London, WC1A 1DG, United Kingdom | Company Director | British |
| Elizabeth McKee Anderson | 79 New Oxford Street, London, WC1A 1DG, United Kingdom | Company Director | US |
| Charles Bancroft | 79 New Oxford Street, London, WC1A 1DG, United Kingdom | Company Director | US |
| Dr. Hal Barron | 79 New Oxford Street, London, WC1A 1DG, United Kingdom | Company Director | US |
| Dr. Anne Beal | 79 New Oxford Street, London, WC1A 1DG, United Kingdom | Company Director | US |
| Wendy Becker | 79 New Oxford Street, London, WC1A 1DG, United Kingdom | Company Director | British & US & Italian |
| Dr. Harry (Hal) Dietz | 79 New Oxford Street, London, WC1A 1DG, United Kingdom | Company Director | US |
| Dr. Gavin Screaton | 79 New Oxford Street, London, WC1A 1DG, United Kingdom | Company Director | British |
| Jeannie Tsun-Huei Lee | 79 New Oxford Street, London, WC1A 1DG, United Kingdom | Company Director | US |
| Dr. Vishal Sikka | 79 New Oxford Street, London, WC1A 1DG, United Kingdom | Company Director | US |
| **GSK Leadership Team** | **GSK Leadership Team** | **GSK Leadership Team** | **GSK Leadership Team** |
| Emma Walmsley | 79 New Oxford Street, London, WC1A 1DG, United Kingdom | Chief Executive Officer | British |
| Julie Brown | 79 New Oxford Street, London, WC1A 1DG, United Kingdom | Chief Financial Officer | British |
| Diana Conrad | 79 New Oxford Street, London, WC1A 1DG, United Kingdom | Chief People Officer | Canadian |
| James Ford | 79 New Oxford Street, London, WC1A 1DG, United Kingdom | SVP and Group General Counsel, Legal and Compliance | British & US |
| Sally Jackson | 79 New Oxford Street, London, WC1A 1DG, United Kingdom | SVP, Global Communications and CEO Office | British |
| Luke Miels | 79 New Oxford Street, London, WC1A 1DG, United Kingdom | Chief Commercial Officer | Australian |
| Shobana Ramakrishnan | 79 New Oxford Street, London, WC1A 1DG, United Kingdom | Chief Digital & Technology Officer | US |
| David Redfern | 79 New Oxford Street, London, WC1A 1DG, United Kingdom | President, Corporate Development | British |
| Regis Simard | 79 New Oxford Street, London, WC1A 1DG, United Kingdom | President, Global Supply Chain | French & British |
| Philip Thomson | 79 New Oxford Street, London, WC1A 1DG, United Kingdom | President, Global Affairs | British |
| Deborah Waterhouse | 79 New Oxford Street, London, WC1A 1DG, United Kingdom | CEO, ViiV Healthcare and President Global Health, GSK | British |
| Tony Wood | 79 New Oxford Street, London, WC1A 1DG, United Kingdom | Chief Scientific Officer | British |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**CureVac N.V.**

*(Name of Issuer)*

**Common Shares, par value (euro) 0.12 per share**

*(Title of Class of Securities)*

**N2451R105**

*(CUSIP Number)*

**Victoria A. Whyte**<br>79 New Oxford Street<br>London X0 WC1A 1DG<br>44 020 8047 5000

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**08/07/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **N2451R105** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**GSK plc** | Name of reporting person<br>**GSK plc** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X0** | Citizenship or place of organization<br>**X0** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**16591937.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**16591937.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**16591937.00** | Aggregate amount beneficially owned by each reporting person<br>**16591937.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**74%** | Percent of class represented by amount in Row (11)<br>**74%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**HC** | Type of Reporting Person (See Instructions)<br>**HC** | |

---

**Comment for Reporting Person:** (1) Common Shares (as defined below) held directly by Glaxo Group Limited, an indirect wholly-owned subsidiary of GSK plc.

(2) Based on 225,172,749 Common Shares outstanding as of close of business on June 10, 2025, as set forth in Exhibit 99.1 to the Form 6-K filed by the Issuer with the Securities and Exchange Commission (the "SEC") on June 16, 2025.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Shares, par value (euro) 0.12 per share

**(b) Name of Issuer:**
CureVac N.V.

**(c) Address of Issuer's Principal Executive Offices:**
Friedrich-Miescher-Strasse 15, Tubingen, 2M, 72076

This statement on Schedule 13D (this "Schedule 13D") relates to the common shares, par value (euro) 0.12 par value per share (the "Common Shares"), of CureVac N.V., a public limited liability company (naamloze vennootschap) organized under the laws of The Netherlands (the "Issuer"), whose principal executive offices are located at Friedrich-Miescher-Strasse 15, 72076 Tubingen, Germany

**Item 4. Purpose of Transaction**

GSK acquired ownership of the Common Shares reported herein for investment purposes and such acquisitions were made in GSK's ordinary course of business and not with any purpose, or with the effect, of changing or influencing the control of the Issuer, or in connection with or as a participant in any transaction having that purpose or effect.

GSK filed with the SEC an initial Schedule 13G on August 24, 2020, to report its acquisition of beneficial ownership of 14,935,721 Common Shares, and filed Amendment No. 1 to its Schedule 13G on February 6, 2024, to report the change in the number of Common Shares beneficially owned by GSK (such filings together, the "Schedule 13G").  GSK is filing this Schedule 13D to supersede the Schedule 13G as a result of the entry by GGL into the Tender and Support Agreement (as defined and described below).

GGL has entered into a Tender and Support Agreement, dated August 7, 2025 (the "Tender and Support Agreement"), with BioNTech SE, a European stock corporation (Societas Europaea) organized under the Laws of Germany and the European Union (the "Buyer"), pursuant to which GGL has agreed to, among other things: (i) tender all of its Common Shares into the exchange offer (the "Exchange Offer") that the Buyer has agreed to commence for any and all of the outstanding Common Shares for the consideration and upon the terms and subject to the conditions set forth in that certain Purchase Agreement, dated June 12, 2025, between the Buyer and the Issuer (as may be amended from time to time, the "Purchase Agreement"); (ii) vote in favor of certain proposals to facilitate the Exchange Offer to be submitted by the Issuer for approval by the Issuer's shareholders and recommended by its management and supervisory boards, and against any proposal, action or agreement for an Alternative Acquisition Proposal (as defined in the Purchase Agreement) or having certain adverse effects on the Exchange Offer or certain post-offer reorganization steps; (iii) certain other restrictions on its ability to take actions with respect to the Issuer and the Common Shares; and (iv) subject to certain conditions under the Tender and Support Agreement, terminate with effect for itself the ISA (as defined below), effective as of the first settlement date of the Exchange Offer.

The foregoing description of the Tender and Support Agreement, and the transactions contemplated thereby, does not purport to be complete and is qualified in its entirety by reference to such agreement.  A copy of the Tender and Support Agreement is filed as Exhibit 2 hereto.

Except as set forth in this Item 4, GSK and GGL have no plans or proposals that relate to or would result in any of the events set forth in Items 4(a) through (j) of Schedule 13D.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The responses of GSK to Rows (7) through (13) of the cover pages of this Schedule 13D and the information set forth in Item 3 are hereby incorporated by reference in this Item 5.  The percentage of the class of securities identified pursuant to Item 1 beneficially owned by GSK is based on 225,172,749 Common Shares outstanding as of close of business on June 10, 2025, as contained in Exhibit 99.1 to the Form 6-K filed by the Issuer with the SEC on June 16, 2025.

**(b)**
Except as disclosed in this Schedule 13D, neither GSK nor, to the best of its knowledge, any of the persons listed in Schedule A hereto, beneficially owns any Common Shares or has the right to acquire any Common Shares. Except as disclosed in this Schedule 13D, neither GSK nor, to the best of its knowledge, any of the persons listed in Schedule A hereto, presently has the power to vote or to direct the vote or to dispose or direct the disposition of any of the Common Shares that they may be deemed to beneficially own.

**(c)**
Except as disclosed in this Schedule 13D, neither GSK nor, to the best of its knowledge, any of the persons listed in Schedule A hereto, has effected any transaction in the Common Shares during the past 60 days.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Investment and Shareholders' Agreement

CureVac AG and certain pre-IPO shareholders of CureVac AG, including GGL, entered into an Investment and Shareholders' Agreement, dated as of July 17, 2020 ("ISA").  The ISA provided for certain particular shareholders' rights and also envisaged restrictions on the shareholders party thereto, including the obligation to enter into a registration rights agreement, restrictions on transfer, as well as certain tag along rights, drag along rights, demand rights, rights of first offer and rights of first refusal.  Following the listing of the Common Shares on Nasdaq, only certain limited provisions of the ISA survived, including (but not limited to) provision of information by the Issuer to the pre-IPO shareholders that is mandatory for their tax obligations, continued confidentiality obligations, certain rights relating to the use of proceeds, IPO-related registration and liability protections and other select rights and obligations expressly set out to survive in the ISA.  As noted above, the Tender and Support Agreement contemplates termination of the ISA in respect of GGL, effective as of the first settlement date of the Exchange Offer.

The foregoing description of the ISA does not purport to be complete and is qualified in its entirety by reference to such agreement.  A copy of the ISA is incorporated by reference as Exhibit 2 hereto.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** GSK plc

**Signature:** /s/ Victoria A. Whyte

**Name/Title:** Victoria A. Whyte, Authorized Signatory

**Date:** 08/13/2025